Answers are grounded in this paper and cite their sources.
Preclinical study reveals that repurposed tigecycline suppresses FOXA1 activity and tumor growth in castration-resistant prostate cancer, highlighting a strategy to overcome treatment resistance.
Resistance to androgen receptor signaling inhibitors, including enzalutamide, remains a major obstacle in treating castration-resistant prostate cancer (CRPC). FOXA1, a pioneer transcription factor frequently overexpressed or mutated in prostate cancer, drives disease progression and represents a potential therapeutic target. Through virtual screening, we identified tigecycline, an FDA-approved antibiotic, as a candidate compound that directly targets FOXA1. We assessed its effects on FOXA1 target gene expression and chromatin occupancy using chromatin immunoprecipitation assays in C4‑2 cells. The impact on FOXA1 mutation-driven progression was evaluated using C4‑2 cells stably expressing a FOXA1 point mutant. In vivo efficacy was examined in CRPC xenograft models. Tigecycline inhibited FOXA1 target gene expression and reduced FOXA1 chromatin occupancy. In FOXA1-mutant cells, tigecycline repressed mutant-driven gene expression, suppressed AR signaling activity, and decreased PSA levels, reversing the oncogenic effects driven by the mutant. Notably, tigecycline retained efficacy in FOXA1-mutant cell lines, likely through direct binding to FOXA1. In vivo, tigecycline suppressed CRPC tumor growth and reduced tumor PSA levels. These findings support tigecycline as a potential therapeutic agent for CRPC by targeting FOXA1.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: